The potential of GLP-1 agonists in weight loss has been a topic of ongoing discussion, but FDA approval for obesity has only been granted in the past decade
October 28: Additional information on pricing, medication availability, insurance options, and safety protocols October 1: Removed Henry Meds and replaced with lower-priced MEDVi
Jessica Bartfield, M.D., associate professor of bariatric and weight management surgery, and a physician at Atrium Health Wake Forest Baptist Multidisciplinary Weight Management Center, where bariatric surgeons and obesity medicine specialists work together to treat patients
For example, Novo Nordisk's Rybelsus has accelerated the adoption of oral GLP-1 therapies across multiple healthcare markets
Its triple agonist mechanism offers superior efficacy compared to existing therapies, with potential benefits for NAFLD and cardiovascular health
Thigh injections tend to absorb slightly slower than abdominal injections, which some researchers find helpful for managing initial side effects
